Compare HCA Health Inc (HCA) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs McCormick & Company, Incorporated — how do they compare? HCA Health Inc trades at $371.96 (market cap $82.17B), while McCormick & Company, Incorporated trades at $52 (market cap $14.04B). The key difference: HCA Health Inc is far larger — about 5.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| HCA | MKC | |
|---|---|---|
Market Cap | $82.17B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $545.13 | $72.81 |
52-Week Low | $334.32 | $45.60 |
Enterprise Value | $131.08B | $18.65B |
Dividend Yield | 0.84% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $370.74, down 0.12% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and revenue growth to $75.6 billion in 2025. The stock faces headwinds from lowered 2026 guidance and negative news flow, but maintains a solid valuation with a P/E of 12.79 and positive analyst consensus.
The outlook is mixed: attractive valuation and operational strength support upside to the $469.40 price target, but near-term risks from payer mix shifts and legal investigations warrant caution. Long-term growth drivers include capacity expansion and medical advancements, though investor sentiment is currently pressured.
MKC trades at $52.26, up 1.08% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 21.91% net income margin and a low P/E of 8.6, suggesting potential undervaluation. Recent Q2 2026 earnings beat expectations, and the pending Unilever Foods deal is a key strategic focus. Cash flow from operations remains robust at $962.2 million for 2025, though net cash flow was negative $90.2 million due to financing activities.
The outlook is mixed; analyst consensus is a buy with a $59.67 price target, implying 14% upside, but technicals and modest organic growth pose risks. The transformative Unilever deal offers growth potential, yet execution risks and competitive pressures in consumer segments warrant caution. Debt reduction trends are positive, with debt-to-asset ratio improving to 30.34% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
